Strategic Lessons and Takeaways from Best Buy's Acquisition and Divestiture of Current Health
NA
In late 2021, amid a broader pandemic-fuelled surge in remote healthcare and virtual care solutions, electronics retailer Best Buy sought to expand its healthcare footprint under its "Best Buy Health" banner. The cornerstone of this healthcare expansion was the acquisition of Current Health, an at-home care and remote patient monitoring platform, for approximately $400 Million.
At the time, the transaction was positioned as a synergistic masterstroke: Best Buy would combine Current Health's FDA-cleared wearable sensors and clinical platform with the retail giant's massive logistics infrastructure and the in-home tech support of its Geek Squad division.
However, by June 2025, the retail giant shifted its strategy, divesting Current Health back to its original co-founder, Christopher McGhee, for an undisclosed sum, laying off healthcare staff and significantly scaling back its clinical ambitions.
This strategic retreat highlights the profound challenges of merging retail business models with the highly regulated, clinically complex and financially volatile American healthcare sector.
Strategic Lessons and Takeaways
The rise and fall of Best Buy’s clinical healthcare experiment offers critical strategic lessons for corporate strategy at the intersection of retail, technology, and clinical medicine.
Healthcare is Not a Transactional Consumer Good
Retail corporations operate on transactional business models optimised for high-volume inventory turnover, customer convenience, and price transparency. Clinical healthcare, however, is a relationship-based service governed by third-party reimbursement, clinical protocols, and long-term care management. Assuming that retail expertise in consumer logistics can seamlessly transition into managing acute patient care under-estimates the complexity of clinical delivery.
Corporate strategists must recognise that medical technology is only an enabler; it cannot replace the clinical and systemic infrastructure required to treat sick patients.
The Perils of Aligning Capital to Temporary Regulatory Frameworks
Best Buy’s massive investment in Current Health was catalysed by temporary CMS waivers designed to expand hospital capacity during a global public health crisis. Investing hundreds of millions of dollars based on temporary emergency waivers exposes a corporation to severe policy risk.
When Congress and CMS failed to establish a permanent reimbursement pathway for hospital-at-home care, the enterprise market stalled.
Corporate entities should avoid committing significant capital to clinical markets until permanent, predictable reimbursement pathways are established by federal and commercial payers.
Pure Technology Plays Lack Viability in Complex Clinical Settings
The belief that software-as-a-service (SaaS) platforms can operate in healthcare with the same high margins and low overhead seen in other sectors is a common strategic error. Managing acute, complex care at home requires heavy human support services, including 24/7 nursing triage, device sanitisation, compliance monitoring, and patient outreach.
These labour-intensive operations erode typical technology margins. Companies entering this space must prepare for lower-margin, services-heavy operations rather than assuming technology alone can scale clinical models.
Brand Equity Does Not Equal Clinical Trust
Retailers often assume that their strong consumer brand awareness can easily translate into clinical credibility. However, patients and healthcare providers do not view a consumer electronics retailer as a trusted source for medical treatment.
Deploying retail personnel into clinical settings introduces not only operational risks, such as HIPAA data exposure, but also strategic pushback from health systems protective of their patient relationships.
Building true "healthcare equity" requires long-term clinical collaboration, a deep understanding of patient workflows, and alignment with traditional medical providers. Without this foundation, consumer brand giants will continue to find clinical markets highly resistant to disruption.